Results 21 to 30 of about 26,674 (238)

Abatacept and the risk of malignancy: a meta-analysis across disease indications. [PDF]

Rheumatology (Oxford)
Objectives To estimate the association between abatacept use and the incidence of malignancy excluding non-melanomatous skin cancers (NMSCs). Methods Systematic database searches were performed, to April 2024, to identify phase II/III/IV randomized ...
Zuckerman BP, Gibson M, Roy R, Hughes M, Mehta D, Yang Z, Adas M, Ng K, Russell MD, Cope A, Norton S, Galloway J.   +11 more
europepmc   +2 more sources

HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA

Arthritis Research & Therapy, 2021
Background Certain risk alleles associated with autoantibody-positive rheumatoid arthritis (RA) have been linked to poorer prognoses. In patients with autoantibody-positive RA, abatacept shows differential efficacy to tumor necrosis factor inhibitors ...
William Rigby, Jane H. Buckner, S. Louis Bridges, Marleen Nys, Sheng Gao, Martin Polinsky, Neelanjana Ray, Vivian Bykerk   +7 more
doaj   +1 more source

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration

Annals of the Rheumatic Diseases, 2022
Background JAK-inhibitors (JAKi), recently approved in rheumatoid arthritis (RA), have changed the landscape of treatment choices. We aimed to compare the effectiveness of four current second-line therapies of RA with different modes of action, since ...
K. Lauper, M. Iudici, D. Mongin, S. Bergstra, D. Choquette, C. Codreanu, R. Cordtz, D. De Cock, L. Dreyer, O. Elkayam, E. Hauge, D. Huschek, K. Hyrich, F. Iannone, N. Inanç, L. Kearsley‐Fleet, E. Kristianslund, T. Kvien, B. Leeb, G. Lukina, D. Nordström, K. Pavelka, M. Pombo-Suárez, Ž. Rotar, M. Santos, Anja Strangfeld, P. Verschueren, D. Courvoisier, A. Finckh   +28 more
semanticscholar   +1 more source

Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors

Journal of Health Economics and Outcomes Research, 2021
# Background Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint swelling and destruction that leads to severe disability. There are no clear guidelines regarding the order of therapies.
Xue Han, Francis Lobo, Michael S. Broder, Eunice Chang, Sarah N. Gibbs, David J. Ridley, Irina Yermilov   +6 more
doaj   +1 more source

Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

Global & Regional Health Technology Assessment, 2021
Purpose: The objective of this economic evaluation was to compare the cost per responder between upadacitinib and abatacept (intravenous [iv] or subcutaneous [sc]) in patients with moderate-to-severe Rheumatoid Arthritis (RA) in Italy.
Roberto Caporali, Roberto Ravasio, Paola Raimondo, Fausto Salaffi   +3 more
doaj   +1 more source

Interference of the T cell and antigen-presenting cell costimulatory pathway using CTLA4-Ig (abatacept) prevents Staphylococcal enterotoxin B pathology [PDF]

, 2017
Staphylococcal enterotoxin B (SEB) is a bacterial superantigen that binds the receptors in the APC/T cell synapse and causes increased proliferation of T cells and a cytokine storm syndrome in vivo.
Carter, Alun J, Green, A. Christopher, Griffiths, Gareth D, Jones, James T.A., Rijpkema, Sjoerd, Risdall, Jane E, Saraiva, Luisa, Taylor, Chris, Vessillier, Sandrine, Whitfield, Sarah J.C., Williamson, E. Diane   +10 more
core   +2 more sources

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

Annals of the Rheumatic Diseases, 2023
Background The optimal first-line treatment in early rheumatoid arthritis (RA) is debated. We compared clinical and radiographic outcomes of active conventional therapy with each of three biological treatments with different modes of action.
M. Østergaard, R. V. van Vollenhoven, A. Rudin, M. Hetland, M. Heiberg, D. Nordström, M. Nurmohamed, B. Gudbjornsson, L. Ørnbjerg, P. Bøyesen, K. Lend, K. Hørslev-Petersen, T. Uhlig, T. Sokka, G. Grondal, S. Krabbe, J. Lindqvist, I. Gjertsson, D. Glinatsi, M. Kapetanovic, A. Aga, F. Faustini, P. Parmanne, T. Lorenzen, Cagnotto Giovanni, J. Back, O. Hendricks, D. Vedder, T. Rannio, Emma Grenholm, M. Ljoså, E. Brodin, H. Lindegaard, A. Söderbergh, M. Rizk, A. Kastbom, P. Larsson, L. Uhrenholt, S. A. Just, D. Stevens, Trine Bay Laurbjerg, G. Bakland, Inge Christoffer Olsen, E. Haavardsholm, J. Lampa   +44 more
semanticscholar   +1 more source

CD28 between tolerance and autoimmunity: The side effects of animal models [version 1; referees: 2 approved] [PDF]

, 2018
Regulation of immune responses is critical for ensuring pathogen clearance and for preventing reaction against self-antigens. Failure or breakdown of immunological tolerance results in autoimmunity.
A Aruffo, A Levine, A Paterson, A Schneider, B Salomon, C Brunstein, C Camperio, C Dendrou, C Lin, C Peterfy, D Franckaert, D Tyrsin, E Hui, E Mayer, F Lühder, G Burmester, G Freeman, G Suntharalingam, H Gmünder, H Ko, I McInnes, I Vogel, J Esensten, J Gross, J Kremer, J Vahl, K Haanstra, M Kishore, M Kunkl, M Tacke, M Vierboom, M Wagner, N Beyersdorf, N Dilek, N Ohkura, N Poirier, N Porciello, N Porciello, O Acuto, P Emery, P Linsley, P Martin, P Tabares, Q Zhang, R Westhovens, R Westhovens, R Zhang, R Zhang, R Zhang, S Bhela, S Khoury, S Weißmüller, S Yao, T Hünig, T Hünig, T Thauland, T Thaventhiran, X He   +57 more
core   +2 more sources

Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD

Journal of Clinical Oncology, 2021
PURPOSE Severe (grade 3-4) acute graft-versus-host disease (AGVHD) is a major cause of death after unrelated-donor (URD) hematopoietic cell transplant (HCT), resulting in particularly high mortality after HLA-mismatched transplantation.
B. Watkins, M. Qayed, C. McCracken, Brandi Bratrude, K. Betz, Yvonne Suessmuth, A. Yu, S. Sinclair, S. Furlan, S. Bosinger, V. Tkachev, J. Rhodes, A. G. Tumlin, A. Narayan, K. Cribbin, S. Gillespie, T. Gooley, M. Pasquini, K. Hebert, Urvi Kapoor, A. Rogatko, M. Tighiouart, Sungjin Kim, C. Bresee, S. Choi, Jeffrey H Davis, C. Duncan, R. Giller, M. Grimley, Andrew C. Harris, D. Jacobsohn, N. Lalefar, M. Norkin, N. Farhadfar, M. Pulsipher, S. Shenoy, A. Petrovič, K. Schultz, G. Yanik, E. Waller, J. Levine, J. Ferrara, B. Blazar, A. Langston, J. Horan, L. Kean   +45 more
semanticscholar   +1 more source

Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis

Arthritis Research & Therapy, 2021
Objectives The aim of this study was to compare the clinical effectiveness of tofacitinib and abatacept and clarify the impact of the HLA-DRB1 shared epitope (SE) on responses to these treatments in patients with rheumatoid arthritis (RA).
Wataru Hirose, Masayoshi Harigai, Koichi Amano, Toshihiko Hidaka, Kenji Itoh, Kazutoshi Aoki, Masahiro Nakashima, Hayato Nagasawa, Yukiko Komano, Toshihiro Nanki, for the TOF-ABT Study Group   +10 more
doaj   +1 more source